Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel
betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, …

Background No therapeutics have yet been proven effective for the treatment of severe
illness caused by SARS-CoV-2. Methods We conducted a randomized, controlled, open-label …

Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large
number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural …

Background The long-term health consequences of COVID-19 remain largely unclear. The
aim of this study was to describe the long-term health consequences of patients with COVID-…

Background Patients with cancer are a high-risk population in the COVID-19 pandemic. We
aimed to describe clinical characteristics and outcomes of patients with cancer and COVID-…

Background A COVID-19 outbreak started in Wuhan, China, last December and now has
become a global pandemic. The clinical information in caring of critically ill patients with COVID-…

The outbreak of a novel coronavirus disease (COVID-19, caused by the 2019-nCoV infection)
in December 2019 is one of the most severe public health emergencies since the founding …

Background The long-term health consequences of COVID-19 remain largely unclear. The
aim of this study was to describe the long-term health consequences of patients with COVID-…

Background Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-…

Background: Human infections with zoonotic coronaviruses (CoVs), including severe acute
respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, have …